Literature DB >> 16968365

Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish "Parachute Project" and two comparison groups.

J Cullberg1, M Mattsson, S Levander, R Holmqvist, L Tomsmark, C Elingfors, I-M Wieselgren.   

Abstract

OBJECTIVE: To evaluate "need-specific treatment" of first episode schizophrenia syndrome patients.
METHOD: Sixty-one consecutive first episode schizophrenia syndrome patients were followed over 3 years. They were compared with a Historical "treatment as usual" group (n = 41) and a Prospective group from a high quality social and biological psychiatry centre (n = 25).
RESULTS: Symptomatic and functional outcome was significantly better compared with the Historical group and equal with the Prospective group. During the first year, the direct costs for in- and out-patient care per patient in the Parachute project were less than half of those in the Prospective group.
CONCLUSION: The study confirms the feasibility, clinically and economically, with a large scale application of "need-specific treatments" for first episode psychotic patients.

Entities:  

Mesh:

Year:  2006        PMID: 16968365     DOI: 10.1111/j.1600-0447.2006.00788.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  12 in total

1.  Integrated treatment and implications for off-medication periods.

Authors:  Johan Cullberg
Journal:  Schizophr Bull       Date:  2006-02-03       Impact factor: 9.306

2.  Psychometric evaluation of the Danish and Swedish Satisfaction with Life Scale in first episode psychosis patients.

Authors:  Jacek Hochwälder; Maria Mattsson; Ragnhild Holmqvist; Johan Cullberg; Bent Rosenbaum
Journal:  Qual Life Res       Date:  2012-05-15       Impact factor: 4.147

3.  Public-academic partnerships: early intervention for psychotic disorders in a community mental health center.

Authors:  Vinod H Srihari; Nicholas J K Breitborde; Jessica Pollard; Cenk Tek; Leslie Hyman; Linda K Frisman; Thomas H McGlashan; Selby Jacobs; Scott W Woods
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

Review 4.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

5.  Cost Analysis of Community Based Family Support of Patients with Severe Mental Illness.

Authors:  Marie Konge Villemoes; Jørgen Aagaard; Ulla Væggemose; Rikke Søgaard
Journal:  Community Ment Health J       Date:  2017-11-25

6.  Effects of Community Mental Health Service in Subjects with Early Psychosis: One-Year Prospective Follow Up.

Authors:  Eun-Jin Na; Nam-In Kang; Mi-Young Kim; Yin Cui; Hee-Eon Choi; Ae-Ja Jung; Young-Chul Chung
Journal:  Community Ment Health J       Date:  2015-11-28

7.  Five-year outcome of first-episode psychosis before and after the implementation of a modified assertive community treatment programme.

Authors:  Robert Bodén; Johan Sundström; Eva Lindström; Ing-Marie Wieselgren; Leif Lindström
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-08-04       Impact factor: 4.328

Review 8.  Is early intervention for psychosis feasible and effective?

Authors:  Vinod H Srihari; Jai Shah; Matcheri S Keshavan
Journal:  Psychiatr Clin North Am       Date:  2012-07-21

9.  Is early intervention in psychosis cost-effective over the long term?

Authors:  Cathrine Mihalopoulos; Meredith Harris; Lisa Henry; Susy Harrigan; Patrick McGorry
Journal:  Schizophr Bull       Date:  2009-06-09       Impact factor: 9.306

10.  Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program.

Authors:  Robert Rosenheck; Douglas Leslie; Kyaw Sint; Haiqun Lin; Delbert G Robinson; Nina R Schooler; Kim T Mueser; David L Penn; Jean Addington; Mary F Brunette; Christoph U Correll; Sue E Estroff; Patricia Marcy; James Robinson; Joanne Severe; Agnes Rupp; Michael Schoenbaum; John M Kane
Journal:  Schizophr Bull       Date:  2016-01-31       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.